QUÉBEC, QC — January 20, 2026 — Leads & Copy — Devonian Health Group Inc. will consolidate its outstanding common shares following shareholder approval of 99.79%. The consolidation (reverse stock split) will be on the basis of one new common share for every sixty currently outstanding.
Devonian (TSXV: GSD) (OTCQB: DVHGF) believes a higher trading price could broaden the pool of investors, and enable the company to meet minimum trading price requirements for listing on U.S. and other stock exchanges.
The company’s board of directors and officers determined the consolidation ratio based on parameters authorized by shareholders at the annual and special meeting on March 20, 2025. The consolidation is subject to final acceptance by the TSX Venture Exchange (TSXV).
Devonian intends to complete the consolidation at the open of market on or around January 22, 2026. Trading on the TSXV is expected to begin on a post-consolidation basis on or around the same date under the symbol “GSD”.
The OTCQB Venture Market trading symbol will remain unchanged, but a “D” will be temporarily added as the fifth character for 20 business days starting the effective date. The new CUSIP number for the common shares will be 251834883, and the new ISIN number will be CA2518348834.
Currently, Devonian has 165,943,512 common shares issued and outstanding. Post-consolidation, the company expects to have approximately 2,765,725 common shares issued and outstanding, subject to issuances prior to the consolidation and rounding for fractional shares. No fractional shares will be issued; the number of post-consolidation shares will be rounded to the nearest whole share.
Holders of uncertificated shares will have their book-entry accounts adjusted electronically by the company’s transfer agent. Beneficial shareholders will have adjustments made by their brokerage firm, banks, trusts, or other nominees. These holders need not take additional action.
Registered shareholders holding share certificates will receive a letter of transmittal with instructions to surrender their pre-consolidation certificates for replacement certificates or a direct registration advice.
After the effective date, each share certificate formerly representing pre-consolidation common shares will represent the number of whole post-consolidation common shares the holder is entitled to.
Devonian Health Group Inc. specializes in developing drugs for autoimmune fibroinflammatory diseases with novel therapeutic approaches to targeting unmet medical needs. Their core strategy involves prescription drugs for treating fibroinflammatory autoimmune diseases such as atopic dermatitis, radiodermatitis, and ulcerative colitis.
Devonian also develops high-value cosmeceutical products and owns a commercialization subsidiary, Altius Healthcare LP, which sells prescription pharmaceutical products in Canada under licenses.
Devonian Health Group Inc., incorporated in 2015 and headquartered in Quebec, Canada, owns a state-of-the-art extraction facility. It is publicly traded on the TSX Venture Exchange (TSXV: GSD) and quoted on the OTCQB Venture Market (OTCQB: DVHGF).
For more information, visit www.groupedevonian.com.
Source: Devonian Health Group Inc.
